Last reviewed · How we verify
bOPV/IPV (6 & 14 weeks)
bOPV/IPV vaccine stimulates the body's immune response to produce antibodies against poliovirus and Haemophilus influenzae type b.
bOPV/IPV vaccine stimulates the body's immune response to produce antibodies against poliovirus and Haemophilus influenzae type b. Used for Protection against poliovirus and Haemophilus influenzae type b infections.
At a glance
| Generic name | bOPV/IPV (6 & 14 weeks) |
|---|---|
| Sponsor | Centers for Disease Control and Prevention |
| Modality | Biologic |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
The bOPV/IPV vaccine contains inactivated poliovirus and Haemophilus influenzae type b antigens. Upon administration, the antigens stimulate the body's immune system to produce antibodies that provide immunity against poliovirus and Haemophilus influenzae type b infections.
Approved indications
- Protection against poliovirus and Haemophilus influenzae type b infections
Common side effects
- Pain, redness, or swelling at the injection site
Key clinical trials
- Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants (PHASE3)
- Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV) (PHASE4)
- A Study to Evaluate Pharyngeal Immunity to Poliovirus Type-2 (PHASE4)
- A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine (PHASE2)
- Immunogenicity of Novel Oral Poliovirus Vaccine Type 2 (nOPV2), bOPV and IPV (PHASE4)
- Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity Study (PHASE4)
- Duration of IPV Priming and Antibody Decay (PHASE4)
- Use of mOPV1 in Routine Immunization in Pakistan. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bOPV/IPV (6 & 14 weeks) CI brief — competitive landscape report
- bOPV/IPV (6 & 14 weeks) updates RSS · CI watch RSS
- Centers for Disease Control and Prevention portfolio CI